Statins in stroke: prevention, protection and recovery

References

• The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med. 333(24), 1581–1587 (1995).
   PubMed Web of Science ®Google Scholar
• Brown DL, Lisabeth LD, Garcia NM, Smith MA, Morgenstern LB. Emergency department evaluation of ischemic stroke and TIA: the BASIC project. Neurology 63(12), 2250–2254 (2004).
   PubMed Web of Science ®Google Scholar
• Heuschmann PU, Berger K, Misselwitz B et al. Frequency of thrombolytic therapy in patients with acute ischemic stroke and the risk of in-hospital mortality: the German stroke registers study group. Stroke 34(5), 1106–1113 (2003).
   PubMed Web of Science ®Google Scholar
• Kwan J, Hand P, Sandercock P. Improving the efficiency of delivery of thrombolysis for acute stroke: a systematic review. Q. J. Med. 97(5), 273–279 (2004).
   Google Scholar
• Reed SD, Cramer SC, Blough DK, Meyer K, Jarvik JG. Treatment with tissue plasminogen activator and in-patient mortality rates for patients with ischemic stroke treated in community hospitals. Stroke 32(8), 1832–1840 (2001).
   PubMed Web of Science ®Google Scholar
• Wolf PA, Clagett GP, Easton JD et al. Preventing ischemic stroke in patients with prior stroke and transient ischemic attack: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke 30(9), 1991–1994 (1999).
   PubMed Web of Science ®Google Scholar
• Collins R, Peto R, MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet335(8693), 827–838 (1990).
   PubMed Web of Science ®Google Scholar
• Kawachi I, Colditz GA, Stampfer MJ et al. Smoking cessation and decreased risk of stroke in women. JAMA 269(2), 232–236 (1993).
   PubMed Web of Science ®Google Scholar
• MacMahon S, Peto R, Cutler J et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet335(8692), 765–774 (1990).
   PubMed Web of Science ®Google Scholar
• Wolf PA, D'Agostino RB, Kannel WB et al. Cigarette smoking as a risk factor for stroke. The Framingham Study. JAMA 259(7), 1025–1029 (1988).
   PubMed Web of Science ®Google Scholar
• Atkins D, Psaty BM, Koepsell TD et al. Cholesterol reduction and the risk for stroke in men. A meta-analysis of randomized, controlled trials. Ann. Intern. Med.119(2), 136–145 (1993).
   PubMed Web of Science ®Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT). JAMA 288(23), 2998–3007 (2002).
   PubMed Web of Science ®Google Scholar
• No authors listed. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet344(8934), 1383–1389 (1994).
   PubMed Web of Science ®Google Scholar
• No authors listed. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The long-term intervention with pravastatin in ischaemic disease (LIPID) Study Group. N. Engl. J. Med. 339(19), 1349–1357 (1998).
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet360(9326), 7–22 (2002).
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. 335(14), 1001–1009 (1996).
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet361(9364), 1149–1158 (2003).
   PubMed Web of Science ®Google Scholar
• Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet360(9346), 1623–1630 (2002).
   PubMed Web of Science ®Google Scholar
• Demchuk AM, Hess DC, Brass LM, Yatsu FM. Is cholesterol a risk factor for stroke?: Yes. Arch. Neurol. 56(12), 1518–1520; discussion 1524 (1999).
   PubMedGoogle Scholar
• Donnan GA, Davis SM. Stroke and cholesterol: weakness of risk versus strength of therapy. Stroke35(6), 1526 (2004).
   PubMed Web of Science ®Google Scholar
• Landau WM. Is cholesterol a risk factor for stroke? No. Arch. Neurol. 56(12), 1521–1524 (1999).
   PubMedGoogle Scholar
• Piechowski-Jozwiak B, Bogousslavsky J. Cholesterol as a risk factor for stroke: the fugitive? Stroke 35(6), 1523–1524 (2004).
   PubMed Web of Science ®Google Scholar
• Thrift AG. Cholesterol is associated with stroke, but is not a risk factor. Stroke 35(6), 1524–1525 (2004).
   PubMed Web of Science ®Google Scholar
• Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration. Lancet346(8991–8992), 1647–1653 (1995).
   PubMed Web of Science ®Google Scholar
• Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N. Engl. J. Med. 320(14), 904–910 (1989).
   PubMed Web of Science ®Google Scholar
• Tanaka H, Ueda Y, Hayashi M. Risk factors for cerebral hemorrhage and cerebral infarction in a Japanese rural community. Stroke 13(1), 62–73 (1982).
   PubMed Web of Science ®Google Scholar
• Yano K, Reed DM, MacLean CJ. Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program. Stroke 20(11), 1460–1465 (1989).
   PubMed Web of Science ®Google Scholar
• Lindenstrom E, Boysen G, Nyboe J. Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen City Heart Study. BMJ 309(6946), 11–15 (1994).
   PubMed Web of Science ®Google Scholar
• Koren-Morag N, Tanne D, Graff E, Goldbourt U. Low- and high-density lipoprotein cholesterol and ischemic cerebrovascular disease: the bezafibrate infarction prevention registry. Arch. Intern. Med.162(9), 993–999 (2002).
   PubMedGoogle Scholar
• Bowman TS, Sesso HD, Ma J et al. Cholesterol and the risk of ischemic stroke. Stroke 34(12), 2930–2934 (2003).
   PubMed Web of Science ®Google Scholar
• Shahar E, Chambless LE, Rosamond WD et al. Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke 34(3), 623–631 (2003).
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Kjekshus J, Pyorala K et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am. J. Cardiol.81(3), 333–335 (1998).
   PubMed Web of Science ®Google Scholar
• Plehn JF, Davis BR, Sacks FM et al. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation99(2), 216–223 (1999).
   PubMed Web of Science ®Google Scholar
• White HD, Simes RJ, Anderson NE et al. Pravastatin therapy and the risk of stroke. N. Engl. J. Med. 343(5), 317–326 (2000).
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333(20), 1301–1307 (1995).
   PubMed Web of Science ®Google Scholar
• Collins R, Armitage J, Parish S et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet363(9411), 757–767 (2004).
   PubMed Web of Science ®Google Scholar
• Amarenco, Tonkin AM. Statins for stroke prevention: disappointment and hope. Circulation109 (23 Suppl.1), III44–III49 (2004).
   PubMedGoogle Scholar
• Schwartz GG, Olsson AG, Ezekowitz MD et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285(13), 1711–1718 (2001).
   PubMed Web of Science ®Google Scholar
• Waters DD, Schwartz GG, Olsson AG et al. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation106(13), 1690–1695 (2002).
   PubMed Web of Science ®Google Scholar
• Crouse JR 3rd, Byington RP, Bond MG et al. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am. J. Cardiol.75(7), 455–459 (1995).
   PubMed Web of Science ®Google Scholar
• MacMahon S, Sharpe N, Gamble G et al. Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group. Circulation97(18), 1784–1790 (1998).
   PubMed Web of Science ®Google Scholar
• Furberg CD, Adams HP Jr, Applegate WB et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation90(4), 1679–1687 (1994).
   PubMed Web of Science ®Google Scholar
• Salonen R, Nyyssonen K, Porkkala E et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation92(7), 1758–1764 (1995).
   PubMed Web of Science ®Google Scholar
• Smilde TJ, van Wissen S, Wollersheim H et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet357(9256), 577–581 (2001).
   PubMed Web of Science ®Google Scholar
• Amarenco P, Labreuche J, Lavallee P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 35(12), 2902–2909 (2004).
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: arterial biology for the investigation of the treatment effects of reducing cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation106(16), 2055–2060 (2002).
   PubMed Web of Science ®Google Scholar
• Lima JA, Desai MY, Steen H, Warren WP, Gautam S, Lai S. Statin-induced cholesterol lowering and plaque regression after 6 months of magnetic resonance imaging-monitored therapy. Circulation110(16), 2336–2341 (2004).
   PubMed Web of Science ®Google Scholar
• Tunick PA, Nayar AC, Goodkin GM et al. Effect of treatment on the incidence of stroke and other emboli in 519 patients with severe thoracic aortic plaque. Am. J. Cardiol.90(12), 1320–1325 (2002).
   PubMed Web of Science ®Google Scholar
• Corvol JC, Bouzamondo A, Sirol M, Hulot JS, Sanchez P, Lechat P. Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials. Arch. Intern. Med.163(6), 669–676 (2003).
   PubMed Web of Science ®Google Scholar
• LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352(14), 1425–1435 (2005).
   PubMed Web of Science ®Google Scholar
• Endres M, Laufs U, Liao JK, Moskowitz MA. Targeting eNOS for stroke protection. Trends Neurosci.27(5), 283–289 (2004).
   PubMed Web of Science ®Google Scholar
• Laufs U. Beyond lipid-lowering: effects of statins on endothelial nitric oxide. Eur. J. Clin. Pharmacol. 58(11), 719–731 (2003).
   PubMed Web of Science ®Google Scholar
• Van Aelst L, D’Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev.11(18), 2295–2322 (1997).
   PubMed Web of Science ®Google Scholar
• Kureishi Y, Luo Z, Shiojima I et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nature Med. 6(9), 1004–1010 (2000).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med. 347(20), 1557–1565 (2002).
   PubMed Web of Science ®Google Scholar
• Rost NS, Wolf PA, Kase CS et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke 32(11), 2575–2579 (2001).
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350(15), 1495–1504 (2004).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cannon CP, Morrow D et al. C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med. 352(1), 20–28 (2005).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Schoenhagen P et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N. Engl. J. Med. 352(1), 29–38 (2005).
   PubMed Web of Science ®Google Scholar
• Lammie GA, Sandercock PA, Dennis MS. Recently occluded intracranial and extracranial carotid arteries. Relevance of the unstable atherosclerotic plaque. Stroke 30(7), 1319–1325 (1999).
   PubMed Web of Science ®Google Scholar
• Liao JK. Beyond lipid lowering: the role of statins in vascular protection. Int. J. Cardiol. 86(1), 5–18 (2002).
   PubMed Web of Science ®Google Scholar
• Di Napoli P, TaccardiAA, Oliver M et al. Statins and stroke: evidence for cholesterol-independent effects. Eur. Heart J. 23(24), 1908–1921 (2002).
   PubMed Web of Science ®Google Scholar
• Endres M, Laufs U, Huang Z et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc. Natl Acad. Sci. USA95(15), 8880–8885 (1998).
   PubMed Web of Science ®Google Scholar
• Laufs U, Gertz K, Huang P et al. Atorvastatin upregulates Type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischaemia in normocholesterolemic mice. Stroke 31(10), 2442–2449 (2000).
   PubMed Web of Science ®Google Scholar
• Amin-Hanjani S, Stagliano NE, Yamada M, Huang PL, Liao JK, Moskowitz MA. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke 32(4), 980–986 (2001).
   PubMed Web of Science ®Google Scholar
• Laufs U, Gertz K, Dirnagl U, Bohm M, Nickenig G, Endres M. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res.942(1–2), 23–30 (2002).
   PubMed Web of Science ®Google Scholar
• Shabanzadeh AP, Shuaib A, Wang CX. Simvastatin reduced ischemic brain injury and perfusion deficits in an embolic model of stroke. Brain Res.1042(1), 1–5 (2005).
   PubMed Web of Science ®Google Scholar
• Sironi L, Cimino M, Guerrini U et al. Treatment with statins after induction of focal ischaemia in rats reduces the extent of brain damage. Arterioscler. Thromb. Vasc. Biol. 23(2), 322–327 (2003).
   PubMed Web of Science ®Google Scholar
• Gertz K, Laufs U, Lindauer U et al. Withdrawal of statin treatment abrogates stroke protection in mice. Stroke 34(2), 551–557 (2003).
   PubMed Web of Science ®Google Scholar
• Greisenegger S, Mullner M, Tentschert S, Lang W, Lalouschek W. Effect of pretreatment with statins on the severity of acute ischemic cerebrovascular events. J. Neurol. Sci.221(1–2), 5–10 (2004).
   PubMed Web of Science ®Google Scholar
• Chen J, Zhang ZG, Li Y et al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann. Neurol.53(6), 743–751 (2003).
   PubMed Web of Science ®Google Scholar
• Marti-Fabregas J, Gomis M, Arboix A et al. Favorable outcome of ischemic stroke in patients pretreated with statins. Stroke 35(5), 1117–1121 (2004).
   PubMed Web of Science ®Google Scholar
• Moonis M, Kane K, Schwiderski U, Sandage BW, Fisher M. HMG-CoA reductase inhibitors improve acute ischemic stroke outcome. Stroke 36(6), 1298–1300 (2005).
   PubMed Web of Science ®Google Scholar
• Stroke Council, American Heart Association; American Stroke Association. Statins after ischemic stroke and transient ischemic attack: an advisory statement from the Stroke Council, American Heart Association and American Stroke Association. Stroke 35(4), 1023 (2004).
   PubMed Web of Science ®Google Scholar
• Ovbiagele B, Kidwell CS, Saver JL. Expanding indications for statins in cerebral ischaemia: a quantitative study. Arch. Neurol. 62(1), 67–72 (2005).
   PubMedGoogle Scholar
• Amarenco P, Bogousslavsky J, Callahan AS et al. Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study. Cerebrovasc. Dis.16(4), 389–395 (2003).
   PubMed Web of Science ®Google Scholar